Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
about
Pneumonia in the neutropenic cancer patientInhaled innate immune ligands to prevent pneumonia.Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma.Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPOverview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursClinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor AnalysisThe colony-stimulating factors: use to prevent and treat neutropenia and its complications.Treatment of elderly cancer patients with chemotherapy.Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studyChemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient settingCOST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Agents under investigation for the treatment and prevention of neutropenia.A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.Prevention of febrile neutropenia: use of prophylactic antibiotics.Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Treatment of the elderly patient with diffuse large B cell lymphoma.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cCosts associated with febrile neutropenia in the US.The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.Myeloid growth factor therapy in malignant lymphomas--a 5-year retrospective study from Hungary.Risk of mortality in patients with cancer who experience febrile neutropenia.Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
P2860
Q26827758-EA059686-1A0F-47A7-B0CC-6243A86981E9Q30398752-EF7A11D4-FB41-46C0-BB3D-0AB187CCFC30Q33389472-D02552F2-7F2F-47A3-BD92-92BCAE184878Q33539387-00C0545A-16AE-49A4-BF6B-198B248703ACQ33861071-74DE6C6B-77E3-46D0-9AB8-DB2684B7A9B0Q34026627-824C57D0-488E-4BBE-B8D4-E1227C77E038Q34528537-519DDC26-48CD-4385-8EB3-CEE058F7CF62Q34635638-D531F06B-CE46-4AC3-A6F6-A1F724E63CFAQ34858123-DC223117-523B-402F-8AD4-9A4C24538441Q35862322-9E73FC77-C5C5-4011-A9A0-462D96FBF1FDQ35967278-575101A4-7C32-4E62-A170-820557F01E05Q36276360-898C80D7-DAD8-487F-B391-599D3831CEC2Q36327074-6202A70C-CD29-4EC5-A505-7F277E26AE9EQ36723952-782D2BD1-B54F-429E-88A1-E1C65D45E63AQ36741541-05DA8252-A87E-4B16-8111-150971D66004Q36853019-316A5317-822F-4C82-A744-4A49B49E37F1Q36985881-9C333B15-6683-4965-A7BB-B17C449AF559Q37320677-9903B4B0-50CE-471A-99D1-13DAB31C6253Q37363332-A2D2BCE7-7055-4AD2-A59E-192094499800Q37363337-11C436E4-CB0C-4F40-ACB2-8C537343BF67Q37703409-A582BD5A-FA68-4D37-A425-AA791EE2DBCFQ37931905-0373D0D3-D217-409A-88CD-4BA73CBC6F4AQ37998553-B9A38770-3F58-42C7-AC29-A25A7F0A865BQ38006021-6155DB9D-18CA-4E5E-87A9-4D1371D44A9CQ38711166-E79650A7-FA4A-4EEB-A08A-A35C31070084Q39074316-E2639B4E-6621-4453-A450-EFE55A0EAEABQ40055208-5C678915-7D35-41CB-BEDE-F5624C361F9EQ40222201-CC4B6CF2-5F5E-483F-B67D-F7EB624881F6Q40274712-72129379-C3A4-4102-B8AA-39EED5A044CFQ40280346-3D892A7D-4C50-4A00-83CC-775176332B0BQ40306765-D46EB4FB-ECAA-422C-A2B7-3A7615DF5ADCQ40349285-EBE757F8-987D-4113-BD06-36DBB122588BQ40351157-0498FD4C-F684-4C8B-9971-8E8A37B5DEE5Q40479380-BF6AA338-89D6-42E7-B073-DCB823ADF830Q41349270-7DE6B8D6-C43B-43B1-BE20-B98D5D6E8D8EQ42361215-F4AC8AEE-F181-46C5-A628-33B5AD0794D1Q42766829-D9F5D55D-E9C1-4C2C-968B-099D02DDED8CQ48606842-1F69E127-6E58-45C0-9A13-FFD0A0DB734FQ50042993-2E766A6F-8FDF-4EAC-956A-0CCEE1008AEAQ51339494-B514B1A2-7082-4EE3-8B0E-76EF3B2361E4
P2860
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Risk and timing of hospitaliza ...... te-grade non-Hodgkin lymphoma.
@en
type
label
Risk and timing of hospitaliza ...... te-grade non-Hodgkin lymphoma.
@en
prefLabel
Risk and timing of hospitaliza ...... te-grade non-Hodgkin lymphoma.
@en
P356
P1433
P1476
Risk and timing of hospitaliza ...... te-grade non-Hodgkin lymphoma.
@en
P2093
David J Delgado
Gary H Lyman
P304
P356
10.1002/CNCR.11827
P407
P577
2003-12-01T00:00:00Z